Foroughinia Farzaneh, Mirjalili Mahtabalsadat
Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Iran J Pharm Res. 2020 Fall;19(4):135-142. doi: 10.22037/ijpr.2020.112292.13670.
Cardiovascular diseases (CVD) have become increasingly life-threatening during recent decades. Several studies have shown that matrix metalloproteinase-9 (MMP-9) plays an important role in the process of atherosclerosis and heart remodeling. On the other hand, Vitamin D deficiency has been recognized as a risk factor for CVD. According to the prevalence of vitamin D deficiency in our country, Iran, we aimed to evaluate the relationship between vitamin D status and the level of MMP-9 in patients undergoing percutaneous coronary intervention. In this prospective cross-sectional study, the patients who were candidates for elective coronary angioplasty were included. Baseline serum MMP-9 and vitamin D levels were measured before intervention. The patients were categorized into three groups: Vitamin D-severely deficient (≤ 10 ng/mL), vitamin D-moderately deficient (11-20 ng/mL), and vitamin D-insufficient/sufficient (> 21 ng/mL). Totally, 150 patients were assessed. The analysis showed that serum MMP-9 levels were higher in patients with lower vitamin-D concentrations. A significant inverse correlation was found between MMP-9 concentration and 25 (OH) vitamin D level ( = 0.039). According to our results, it may be concluded that low levels of vitamin D may lead to more vulnerable atherosclerotic plaques and consequently more cardiovascular adverse effects in post-PCI patients.
近几十年来,心血管疾病(CVD)对生命的威胁日益增加。多项研究表明,基质金属蛋白酶-9(MMP-9)在动脉粥样硬化和心脏重塑过程中起重要作用。另一方面,维生素D缺乏已被认为是心血管疾病的一个危险因素。根据我国伊朗维生素D缺乏的患病率,我们旨在评估接受经皮冠状动脉介入治疗患者的维生素D状态与MMP-9水平之间的关系。在这项前瞻性横断面研究中,纳入了择期冠状动脉血管成形术的候选患者。在干预前测量基线血清MMP-9和维生素D水平。患者分为三组:维生素D严重缺乏(≤10 ng/mL)、维生素D中度缺乏(11-20 ng/mL)和维生素D不足/充足(>21 ng/mL)。总共评估了150例患者。分析表明,维生素D浓度较低的患者血清MMP-9水平较高。发现MMP-9浓度与25(OH)维生素D水平之间存在显著负相关(=0.039)。根据我们的结果,可以得出结论,低水平的维生素D可能导致动脉粥样硬化斑块更易损,从而在PCI术后患者中产生更多心血管不良反应。